Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
In a groundbreaking move, Eli Lilly (NYSE:LLY) is set to test its weight-loss medications on individuals who are not ...
Kailera Therapeutics nets $400 million as weight-loss drug market heats up
The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...
Weight-Loss Drug Cases Push Clinical Definition Into Legal Arena
A series of state and federal lawsuits challenging coverage exclusions for obesity drugs and procedures are testing the ...
WeightWatchers CEO who oversaw diet company’s move into weight loss drugs abruptly leaves role
WeightWatchers is shaking up its leadership. WW International on Friday announced that CEO Sima Sistani would leave her role ...
WeightWatchers CEO suddenly quits after push to embrace weight-loss drugs like Ozempic, Wegovy
Sima Sistani, who took up the CEO post at WW International two-and-a-half years ago, is out, according to the company.
MM&M4m
Roche bets on 3 experimental obesity, diabetes drugs to bring in $3.6 billion a year
The pharma company said it believes there’s plenty of room for multiple industry players in the obesity drug market.
Weight loss drugs like Ozempic and Wegovy are tremendously popular and effective. Patients should also be careful in using them
Semaglutide, the underlying drug marketed as Ozempic and Wegovy, works by mimicking a hormone that triggers the body to feel ...
Weight-loss drugs are life-changing — and expensive. Here's one woman's solution.
A woman who started taking a popular weight loss medication through a clinical trial had to look for alternatives when her ...
The Washington Post7d
Weight-loss drugs are supposed to be forever. Until they run out.
Maez Waibel lost more than 30 pounds in nine months on the new weight-loss drugs, sparking a substantial improvement in health. But instead of feeling happy and relieved, Waibel’s days have been ...
STAT3h
$400 million for an obesity drug startup? A new venture is a sign of the times
Atlas Venture and Bain Capital Life Sciences are making their next bet in the buzzy obesity field, launching a new startup ...